Replies to post #130430 on PharmaCyte Biotech Inc (PMCB)

[DragonBear]

No one funds something-or performs an acquisition

without reaping the benefits and there are no benefits to reap here

Literally yrs from now if approved, and marketed, the Kenny Wonder Treatment might fit into the niche of a palliative treatment for 2nd line PC. Nothing more. Lessen the metastatic tumor load, patient feels better for 2-3 months before dying. That's assuming it can be proven the presence of CIABs are required in addition to Metronomic Ifosfamide. One wonders how many Oncologists have used Cytoxin for that purpose in terminal PC patients.

So, what is the revenue in a current niche market for a 2nd line PC palliative treatment? Using a generic chemo drug one does not manufacture? Maybe $5-10M/yr if lucky. Now divide that by 2B shares. No one is going to acquire PMCB for multi-billions, and then take 400 yrs to recoup their acquisition expenses. The world just doesn't operate that way.